Prevention of cancer by prophylactic human papillomavirus vaccines

被引：24

作者：

Kwak, Kihyuck ^{[1
]}

Yemelyanova, Anna ^{[1
]}

Roden, Richard B. S. ^{[1
,2
,3
]}

机构：

[1] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21231 USA

[2] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21231 USA

[3] Johns Hopkins Univ, Dept Gynecol & Obstet, Baltimore, MD 21231 USA

来源：

CURRENT OPINION IN IMMUNOLOGY | 2011年 / 23卷 / 02期

基金：

美国国家卫生研究院;

关键词：

VIRUS-LIKE PARTICLES; MINOR CAPSID PROTEIN; ANTIBODY-RESPONSES; IMMUNE-RESPONSES; FUSION PROTEIN; DOUBLE-BLIND; YOUNG-WOMEN; L1; PROTEIN; HPV TYPES; B-CELL;

D O I：

10.1016/j.coi.2010.11.009

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Oncogenic human papillomaviruses (HPVs) are exclusively mucosal pathogens that are noncytopathic and the basal epithelial cells harboring and maintaining an infection do not produce either capsid antigen or virus. The efficacy of the licensed L1 virus-like particle (VLP) vaccines has encouraged development of several second generation vaccines aimed at expanding the coverage to all oncogenic HPV types and reducing barriers to global implementation. Currently there is no defined immune correlate of protection that can be used to determine if an individual patient is protected and for the evaluation of these second generation vaccines. Surprisingly, passive transfer of neutralizing serum antibody is protective in animal models. Recent studies suggest how neutralizing antibody mediates immunity against mucosal HPV and the possible impact of memory B cells.

引用

页码：244 / 251

页数：8

共 50 条

[21] Prophylactic human papillomavirus vaccines: past, present and future
Anderson, Lyndal A.
PATHOLOGY, 2012, 44 (01) : 1 - 6
[22] Prophylactic human papillomavirus vaccines: potential for sea change
Ferencz, Alex
Franco, Eduardo L.
EXPERT REVIEW OF VACCINES, 2007, 6 (04) : 511 - 525
[23] Human Papillomavirus Vaccines for Cervical Cancer Prevention: Translating Possibility Into Reality
Sahasrabuddhe, Vikrant V.
Sherman, Mark E.
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (22) : 1698 - 1701
[24] Human papillomavirus vaccines launch a new era in cervical cancer prevention
Dawar, Meenakshi
Deeks, Shelley
Dobson, Simon
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2007, 177 (05) : 456 - 461
[25] Vaccines against human papillomavirus and perspectives for the prevention and control of cervical cancer
García-Carrancá, A
SALUD PUBLICA DE MEXICO, 2003, 45 : S437 - S442
[26] Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines
Einstein, Mark H.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (04) : 443 - 451
[27] Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing
Wheeler, Cosette M.
NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (04): : 224 - 235
[28] Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines
Mark H. Einstein
Cancer Immunology, Immunotherapy, 2008, 57 : 443 - 451
[29] Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing
Cosette M Wheeler
Nature Clinical Practice Oncology, 2007, 4 : 224 - 235
[30] Harnessing the power of prevention: human papillomavirus vaccines
Mayeaux, Edward J., Jr.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2006, 18 : S15 - S21

← 1 2 3 4 5 →